(Reuters) -Kenvue on Thursday warned that a longer summer season in the northern hemisphere would hurt sales of its cold and flu medicines this year as the Benadryl maker cut the higher end of its annual profit forecast range. The consumer health company, which also flagged an increased impact from a stronger dollar, now expects full-year adjusted profit between $1.26 and $1.28 per share, compared with its previous forecast of $1.26 to $1.31 per share. "Mostly due to the seasonally warm weather we saw in the northern hemisphere in September, we see a slow start of the season," CEO Thibaut Mongon told Reuters.